Court grants Abbott injunction against Andrx's generic version of Biaxin pending full trial

By E. Janene Geiss

Philadelphia, Nov. 11 - The U.S. District Court for the District of Northern Illinois granted Abbott Laboratories' request for a preliminary injunction to prevent Ranbaxy and Andrx Corp. from making unauthorized generic copies of Abbott's Biaxin XL pending a full patent infringement trial.

The trial is expected to take place in 2006, although no date has been set, according to an Abbott Laboratories news release.

Andrx Corp. makes Clarithromycin Extended Release tablets, an AB-rated generic equivalent of Abbott's macrolide antiobiotic Biaxin XL Filmtab.

Andrx officials said they were evaluating the court's decision and will determine a course of action, according to an Andrx news release.

Abbott Laboratories is a pharmaceutical company based in Abbott Park, Ill., that develops, manufactures and markets pharmaceuticals, medical products, devices and diagnostics.

Andrx, based in Fort Lauderdale, Fla., is a pharmaceutical company that develops generic versions of controlled-release, niche and immediate-release pharmaceutical products, including oral contraceptives.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.